JPRN-UMIN000029601已完成未知
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study. - A pilot study of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pleural effusion, ascites or pericardial effusion requiring drainage 2)Other cancers 3)Symptomatic brain metastasis and meningitis 4)With severe complication 5)Interstitial pneumonia on CT 6)Severe drug allergy 7)Active autoimmune disease that has required systemic treatment 8)Dementia 9)Other conditions not suitable for this study
研究者
相似试验
已完成
不适用
Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study.on-small cell lung cancerJPRN-UMIN000029602Department of Respiratory Internal medicine, Hiroshima Univestity Hospital35
招募中
2 期
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDNSCLC With COPDNCT05578222Tianjin Chest Hospital30
招募中
2 期
pembrolizumab plus axitinib trialrenal cell carcinomaJPRN-jRCT1061200062Takehiro Iawata7
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerEUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270
进行中（未招募）
1 期
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerEUCTR2014-003574-16-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.253